Navana Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported sales was BDT 1,502.64 million compared to BDT 1,224.83 million a year ago. Net income was BDT 104.98 million compared to BDT 68 million a year ago. Basic earnings per share from continuing operations was BDT 1.09 compared to BDT 0.85 a year ago.
For the nine months, sales was BDT 4,234.62 million compared to BDT 3,662.29 million a year ago. Net income was BDT 248.54 million compared to BDT 191.84 million a year ago. Basic earnings per share from continuing operations was BDT 2.57 compared to BDT 2.39 a year ago.